Principal Financial Group Inc. Decreases Position in Collegium Pharmaceutical, Inc. $COLL

Posted by George Bondi on Jul 19th, 2026

Principal Financial Group Inc. trimmed its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 1.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,295,028 shares of the specialty pharmaceutical company’s stock after selling 18,634 shares during the period. Principal Financial Group Inc.’s holdings in Collegium Pharmaceutical were worth $42,827,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Fifth Third Bancorp raised its holdings in Collegium Pharmaceutical by 16,152.5% during the 1st quarter. Fifth Third Bancorp now owns 29,092 shares of the specialty pharmaceutical company’s stock valued at $962,000 after buying an additional 28,913 shares during the period. Y Intercept Hong Kong Ltd bought a new position in Collegium Pharmaceutical during the first quarter valued at $686,000. James Investment Research Inc. increased its position in Collegium Pharmaceutical by 19.7% during the first quarter. James Investment Research Inc. now owns 7,110 shares of the specialty pharmaceutical company’s stock valued at $235,000 after acquiring an additional 1,170 shares during the last quarter. Peregrine Capital Management LLC purchased a new stake in shares of Collegium Pharmaceutical in the first quarter valued at $3,185,000. Finally, Louisiana State Employees Retirement System purchased a new stake in shares of Collegium Pharmaceutical in the first quarter valued at $463,000.

Collegium Pharmaceutical Trading Down 0.5%

NASDAQ COLL opened at $36.08 on Friday. The stock has a market cap of $1.17 billion, a PE ratio of 17.69 and a beta of 0.73. Collegium Pharmaceutical, Inc. has a 12 month low of $29.19 and a 12 month high of $50.79. The company’s 50-day moving average price is $34.62 and its 200-day moving average price is $38.34. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. The company had revenue of $193.52 million during the quarter, compared to analyst estimates of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter last year, the business posted $1.49 EPS. Equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on COLL shares. Zacks Research raised shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 29th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Finally, Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $57.50.

Get Our Latest Stock Analysis on COLL

Collegium Pharmaceutical Profile

(Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.